Abstract: New insulin analogues with a longer duration of action and a 'peakless' pharmacokinetic profile have been developed to improve efficacy, safety and convenience for patients with diabetes. During non-clinical development, according to regulatory guidelines, these analogues are tested in healthy euglycaemic rats rendering them persistently hypoglycaemic. Little is known about the effect of persistent (24 hr/day) insulin-induced hypoglycaemia (IIH) in rats, complicating interpretation of results in pre-clinical studies with new longer-acting insulin analogues. In this study, we investigated the effects of persistent IIH and their reversibility in euglycaemic rats. Histopathological changes in insulin-infused animals included partly reversible axonal and reversible myofibre degeneration in peripheral nerve and skeletal muscle tissue, respectively, as well as reversible pancreatic islet atrophy and partly reversible increase in unilocular adipocytes in brown adipose tissue. Additionally, results suggested increased gluconeogenesis. The observed hyperphagia, the pancreatic, peripheral nerve and skeletal muscle changes were considered related to the hypoglycaemia. Cessation of insulin infusion resulted in transient hyperglycaemia, decreased food consumption and bodyweight loss before returning to control levels. The implications for the interpretation of non-clinical studies with long-acting insulin analogues are discussed.
Insulin therapy represents a cornerstone in the treatment of type 1 and advanced type 2 diabetes mellitus. However, many patients do not achieve adequate glycaemic control with currently available treatments [1] . Therefore, new insulin analogues with longer duration of action, a more constant and 'peakless' pharmacokinetic profile and a lower intra-individual day-to-day variation remain an unmet therapeutic need. Moreover, such analogues will reduce risk of hypoglycaemia and dosing frequency, thereby increasing safety and convenience for patients [2] .
According to regulatory guidelines, safety evaluations of new insulin analogues during pre-clinical studies are conducted in healthy (euglycaemic) animals [3, 4] . The rat is often chosen as the most appropriate rodent species because of its pharmacological responsiveness to insulin and history of use as an animal model, for prediction of toxic changes in man. Because of the intended pharmacological effect of insulin analogues, that is lowering of blood glucose, healthy rats in repeated-dose studies experience recurrent hypoglycaemia. As this condition can cause histopathological changes [5] , effects of the hypoglycaemia per se may be difficult to separate from potentially relevant off-target effects of a new insulin analogue. Consequently, such discrimination is usually accomplished by including an in-study-comparator group receiving human insulin (HI) once or twice daily [4, 6] . In non-clinical toxicological studies with long-acting insulin analogues, the prolonged duration of action results in persistent hypoglycaemia, that is lowering of the blood glucose level for 24 hr a day. Little is known about the effect of persistent insulininduced hypoglycaemia on metabolic and endocrine regulations in healthy rats. Furthermore, animals receiving HI once or twice daily is not a suitable comparator due to the short half-life of HI in rats (<23 min.) [7] , which would result in recurrent rather than persistent hypoglycaemia. Therefore, we have recently developed a comparator model using continuous HI infusion to healthy rats to mimic the prolonged exposure and persistent hypoglycaemia seen with the long-acting analogues [8] .
In the present study, the effects of persistent hypoglycaemia induced by HI in healthy rats were investigated using standard end-points of toxicity studies including histopathological evaluation.
Materials and Methods
Animals and study design. Male and female Sprague Dawley (Crl:CD (SD)) rats (6-7 weeks old, 60 male and 60 female, n = 120) were supplied by Charles River Limited (UK). Animals were acclimatized to local environmental conditions (19-23°C, 40-70% humidity, 12-hr light-dark cycle, lights on at 6:00 a.m.) for at least 5 days and housed in solid bottom polycarbonate cages with a stainless steel mesh lid and sawdust litter (up to five animals/cage). They were offered a commercial diet (Rat and Mouse No. Infusion. Infusion was achieved by external infusion pumps (Harvard Apparatus Pump 11 Plus Syringe Pump, Harvard Apparatus, Holliston, MA, USA) through a surgically implanted vascular catheter inserted into the caudal vena cava through the right femoral vein as previously described [8] . The test substance used was recombinant human insulin (HI) formulated in a phosphate-buffered vehicle (HI-Low and HI-High groups) and buffered vehicle (CTRL group). Recombinant HI stock solutions in phosphate-buffered vehicle (600 nmol/ml) as well as buffered vehicle were supplied by Novo Nordisk A/S (Maaloev, Denmark). Recombinant HI stock solution and buffered vehicle were diluted with dilution medium to obtain the formulations for infusion. The composition of buffered HI stock formulation, buffered vehicle, and dilution medium was as previously described [8] . Infusion rates (1.4 ml/kg/hr) were adjusted on a weekly basis according to individual body-weight gain to keep doses constant in U/kg/day over the infusion period, whereas insulin concentration was kept constant for each dose level. Infusion formulation was renewed on a daily basis.
Blood glucose level. Two types of blood glucose measurements were included: plasma for glucose profiling (sublingual vein under isoflurane anaesthesia) and whole blood for continuous single timepoint assessment (tail vein, no anaesthesia). The plasma glucose profiles were taken to monitor the decrease in blood glucose levels after start of HI infusion on Day 1, Day 25 and Day 53 to confirm a persistent 24-hr decrease as would be expected from continuous infusion. Furthermore, plasma for glucose profiling was also sampled on Day R1 to follow changes in plasma glucose level after cessation of HI infusion. These samples were taken at the following nominal time-points: 0.25, 0.5, 6, 12 or 24 hr (2 animals/sex/group at each time-point), where the time-points on Day 1 and Day R1 refer to hours after commencement and cessation of infusion, respectively. Furthermore, blood samples for plasma glucose quantification were obtained at a single time-point from all animals on Day 8, and before termination of animals on Day 57 and Day R29. Plasma glucose levels were quantified as described previously [8] . Whole blood was sampled for snap-measuring of glucose levels with an Accu-Check device (Aviva, Cat/Type 05911974002, Roche Diagnostics, Burgess Hill, West Sussex, UK) to monitor whole-blood glucose levels during the study and allow for potential adjustment of dose levels. All animals were sampled twice weekly during the infusion period and the first week of the infusion-free recovery period and once weekly during the remainder of the infusion-free recovery period. The frequency of sampling was reduced if there was a scheduled plasma glucose profile within that week. Samples were taken at approximately the same time (11:30 AE 60 min.) of day on each occasion, if blood volume permitted.
Plasma HI levels and toxicokinetic analysis. On Day 1 and Day 53, blood samples were taken from the sublingual vein for plasma HI quantification at the same time-points as for plasma glucose measurements described above. Levels of HI in plasma were quantified as previously described [8] . The lower limit of quantification (LLOQ) of the assay was 25 pmol/l. Results are reported as the mean of two replicates. For toxicokinetic analysis, composite mean profiles of plasma concentration versus time data from male and female rats were generated and subsequently treated as full profiles. The steady-state concentrations (C ss ) were calculated based on non-compartmental analysis. For a continuous i.v. infusion of HI, the plasma concentration of HI is per definition constant at all time-points. For Day 1, the concentrations from 6 to 24 hr represent C ss , as steady-state is theoretically obtained after 5-7 half-lives (halflife of HI dosed i.v. in rats is approximately 14 min. [7] Louis, MO, USA). 
Results

Animals.
Food consumption was increased in HI-infused animals compared to controls during approximately the first 4 weeks of infusion ( fig. 1A ,B). This was most pronounced during the first week, where food intake was significantly increased by 18-24% in HI-infused males and by 13-16% in HI-infused females (p < 0.001 for all insulin-infused groups versus controls on Day 4 and Day 8). Immediately after HI infusion was stopped, food consumption decreased significantly by approximately 40-50% in males (p < 0.001 for HI-Low and HI-High group versus CTRL group) and 20-40% in females (p < 0.01 and p < 0.001 for HI-Low and HI-high group, respectively, versus CTRL group) for approximately 1 week after which food consumption was similar to control groups. Increased food consumption was accompanied by increased body-weight gain compared to control animals, and this effect was evident throughout the infusion period ( fig. 1C ). At Day 57, bodyweights were increased by 4% and 10% in HI-Low and HIHigh group males, respectively, and 4% in HI-High group females compared with controls, albeit only statistically significant in HI-High group males (p < 0.01). After cessation of infusion, body-weights decreased in previously HI-infused animals, and after 1 week body-weights were comparable to controls. No changes were seen at the in life ophthalmoscopic examination of animals. There were 21 premature deaths (6 CTRL, 8 HI-Low, and 7 HI-High group animals) of the 120 animals included in the study. Two of these were attributed to hypoglycaemia (one HI-High and one HI-Low group animal), one animal died during a blood sampling (HI-High group animal) and 10 were terminated prematurely due to disturbances with the infusion system (e.g. a disconnected or regressed catheter, distributed across all groups). The remaining eight deaths were attributed to poor clinical condition and distributed across all groups including controls. In 4 of these animals, there were signs of infection, such as meningitis, renal microabscesses, myocarditis, abscesses in abdomen, skin and limbs, and/or arthritis.
Blood glucose levels. HI infusion decreased whole-blood glucose levels in both males and females to about 50-70% of controls (7 mM) without significant dose-response relationship ( fig. 2 ). After cessation of infusion, whole-blood glucose levels were similar between all groups, although slightly higher in HI-High group males (p < 0.05) and HI-Low group females (p = 0.141) compared to controls. Plasma glucose levels were decreased at the end of Day 1 in HI-infused animals ( fig. 3A,B) . On Day 25 and Day 53, values in HI-infused groups were generally lower than in the CTRL with values of approximately 5-7 mM versus 8-10 mM in controls in both males and females with no dose-response (statistics were not performed as n = 2/time-point, data not shown). On the first day of the infusion-free recovery period (Day R1), previously HI-infused males generally had higher plasma glucose levels than controls 6-12 hr after cessation of infusion (means up to approximately 15 mM versus 10 mM in controls ( fig. 3C ). In previously HI-infused females, a similar tendency was seen in HI-High group 0.5 and 6 hr after infusion was stopped ( fig. 3D) Haematology and clinical chemistry. No significant changes of haematology parameters were seen after 8 weeks of HI infusion (data not shown), except for a 25% decrease in leucocyte number in HI-High group females (p < 0.05) compared to CTRL females. This change was not present after 4 weeks of infusion-free period (Day R29). A few clinical chemistry parameters were changed in the HIinfused groups. Plasma level of AST was increased in HIHigh group males by 14% (p < 0.05), whereas plasma level of ALP was decreased in HI-High group females by 27% (p < 0.01). Plasma urea concentrations were increased significantly in HI-Low and HI-High group males by 23% (p < 0.01) and 30% (p < 0.01), respectively, compared to the CTRL group males, and in HI-Low group females by 13% (p < 0.05) compared to CTRL group females. Furthermore, plasma sodium levels were increased significantly in HI-Low and HI-High group males by 1% (p < 0.05) and 2% (p < 0.01), respectively. Plasma chloride levels were increased in HI-High group males by 1% (p < 0.01) compared to controls. No other changes were observed on clinical chemical parameters, and no changes were present Day R29, except for the increased sodium levels in HI-Low group males (increased 2% compared to controls on Day R29, p < 0.01).
Urinalysis.
During HI infusion, the specific gravity increased by 1% in HI-High males and females, although only statistically significant in the males (p < 0.05). This was accompanied by a 38-46% decrease in urinary volumes (not statistically significant). Furthermore, in HI-High group males, total urinary glucose output decreased significantly by 45% (p < 0.05 versus CTRL) with no significant changes in the remaining groups (within AE18% of CTRL; fig. 4A ). During the infusion-free recovery period, HI-High group males had increased urinary volume (+132%, p < 0.01) and decreased specific gravity (À1%, p < 0.01). Total urinary glucose output was increased by 118% in HI-High group males compared to CTRL group males, and by 47% and 63% in HI-Low and HI-High group females, respectively, versus CTRL group females ( fig. 4A,B) . However, none of these changes attained statistical significance. There was no other effect of HI infusion upon the composition of the urine (data not shown).
Organ weights and macropathology. Organ weight data were evaluated both as absolute organ weight as well as organ weight related to body-weight. Changes to absolute organ weight: thymus weights of HI-Low and HI-High group males were significantly increased by 36 and 37%, respectively (p < 0.01), and the collective weight of thyroids and parathyroids was increased by 12% in HI-High 2 Glucose levels in this group were significantly lower on Day 57 compared to Day 8 (two-way ANOVA with study day and sex as fixed variables, p = 0.0399 for HI-Low group, and p = 0.0028 for HI-High group. There was no effect of sex). *p < 0.05 and ***p < 0.001 versus CTRL. One value from a HI-Low group male in Week R4 was excluded, as it had a value of 394.6 lmol and was considered an extreme outlier. Week 8: n = 11-17/sex/group, Week R4: n = 2-6/sex/ group. *p < 0.05 versus CTRL group.
group males (p < 0.05). No other changes to absolute organ weights were seen. Changes to body-weight relative organ weights: there was a significant decrease in body-weight relative kidney weights in HI-High group males and females (8 and 10%, respectively; p < 0.05). Additionally, there was a significant decrease of body-weight relative liver weight in HI-Low and HI-High group males (8% and 11% [p < 0.05 and p < 0.01], respectively). No other relative organ weight changes were seen. In some of the animals, macroscopic changes such as thickened vein at the catheter insertion site (femoral vein) and at the catheter tip (vena cava caudalis), dark or pale areas in lungs and bronchi, and enlarged lumbar lymph nodes were seen after 8 weeks of infusion (data not shown). The incidence and distribution of these findings were similar in all groups including the CTRL group. These changes were still present after 4 weeks of infusion-free recovery but with a lower incidence.
Histopathological findings.
Peripheral nervous system. The sciatic nerve, cervical and dorsal root ganglia were evaluated for histopathological changes. No changes were observed in cervical or dorsal root ganglia of HI-High and CTRL group (data not shown), therefore, the tissue from HI-Low group was not examined as per standard procedure in pre-clinical toxicological studies. In the sciatic nerve from the HI-infused males, an increased incidence and severity of axonal degeneration was seen after 8 weeks (table 4A, fig. 5A,B) . After the 4-week infusion-free recovery period, incidence of axonal degeneration was similar across all groups including the CTRL group, but with the changes being more severe in HI-High group males compared to CTRL and HI-Low groups (table 4A) .
Skeletal muscle tissue. In skeletal muscle tissue (quadriceps femoris muscle), 8 weeks of insulin infusion increased the incidence of myofibre degeneration and inflammatory cell infiltrate (table 4B, fig. 5C,D) . Incidence of myofibre degeneration was approximately two-times higher in HI-infused males compared to HI-infused females, but with no doseresponse in either sex. Also the incidence of inflammatory cell infiltrate was higher in males than in females. After 4 weeks of infusion-free recovery, myofibre degeneration and inflammatory cell infiltrate in skeletal muscle tissue had comparable incidence levels to the CTRL group.
Pancreas. There was an increased incidence of islet cell atrophy in pancreas after insulin infusion in both HI-Low and HI-high groups (table 4C, fig. 5E,F) . There was no doseresponse and no difference between males and females. After 4 weeks of infusion-free recovery, pancreatic islet cell atrophy was still present in a few animals.
Adipose tissue. In the brown fat between the shoulder blades as well as brown fat around the aorta, a dose-related increased incidence of unilocular adipocytes was observed in HI-infused animals (table 4D, fig. 5G,H) , with similar severity between HI-High and HI-Low groups. There was a similar incidence and severity of changes between males and females. In aortic brown fat, similar but less pronounced changes were noted (table 4D) . After 4 weeks of infusion-free recovery, the incidence of these changes were similar in previously HIinfused females and CTRL group, but still higher in previously HI-infused males compared to CTRL group, although with lower incidence than after 8 weeks of HI infusion in the same groups.
Lungs. Granulomas were found in lungs after 8 weeks, with a similar incidence across all groups including CTRL group, but severity was higher in HI-High group males and females versus controls (table 5) . Incidence was lower after 4 weeks of recovery in all groups except HI-High group females. In addition, changes observed in lungs of animals infused for 8 weeks included thromboemboli with mineralization, alveolar aggregation of foamy macrophages, perivascular inflammatory cell infiltrate, and alveolitis (data not shown), but with similar incidences across all groups including the CTRL group. After 4 weeks of infusion-free recovery, perivascular inflammatory cell infiltrate and alveolitis could still be observed in some animals.
Infusion catheter. Only tissue from CTRL and HI-High group was evaluated after 8 weeks of infusion unless otherwise mentioned. All changes related to the infusion catheter were observed with similar incidence and severity across groups. In the majority of the animals: epidermal hyperplasia and granulomatous inflammation at the cutaneous exteriorization site of the infusion catheter, and suture granulomas at the vein insertion site of the infusion catheter (femoral vein). Additionally, granulomatous inflammation (10-50%), abscesses (0-30%), and/or thrombi (0-20%) were present in some animals. At the vein infusion site at the catheter tip (caudal vena cava, all groups evaluated), there was a high incidence of vascular intimal nodular proliferation (75-91%), as well as intravenous thrombi (40-100%) at the catheter tip. Microscopic examination of the vein 1 cm from the catheter tip revealed thrombi in 0-50% of the animals in each group.
Other findings. Four CTRL females had minimal to moderate interstitial inflammatory cell infiltrate in the kidneys and several animals in both the CTRL and HI-High groups had tubular basophilia after 8 weeks of infusion (HI-Low group not evaluated). This was not present on Day R29. In the liver, inflammatory cell infiltrate and centrilobular hepatocellular vacuolization were present in several animals after 8 weeks of infusion as well as 4 weeks of infusion-free recovery, but with similar incidence and severity across all groups including the CTRL group. After 8 weeks of infusion, generally, a few animals in each group had generalized increased cellularity and mastocytosis of the lumbar, left and right axillary, and right inguinal lymph nodes, but generally no changes in the left inguinal lymph node, with similar incidence and severity across groups. This was not seen after 4 weeks of infusionfree recovery.
Discussion
In the present study, the effects of persistent hypoglycaemia (i.e. lowering of blood glucose levels 24 hr/day) induced by continuous HI infusion in healthy rats were investigated using standard end-points of toxicity studies including histopathological evaluation. Effects of persistent hypoglycaemia in healthy rats needed clarification to aid the interpretation of results from pre-clinical testing of new long-acting insulin analogues. Persistent IIH caused histopathological changes directly or indirectly attributable to the induced hypoglycaemia, such as in peripheral nerve, skeletal muscle, and pancreas and/or to the hyperinsulinaemia, such as might be the case in brown fat tissue. Overall, many of the toxicological changes observed reflected a counterregulatory response to the hypoglycaemia characterized by hyperphagia and increased gluconeogenesis. The majority of these changes were completely reversible after 4 weeks and the remaining were partially reversible within this period. The axonal and myofibre degeneration induced by IIH over 8 weeks in sciatic nerve and skeletal muscle tissue, respectively, in the present study confirmed the findings of a previous 4-week study with HI infusion in rats [8] . Additionally, the present study showed increased incidence of inflammatory cell infiltration in skeletal muscle tissue in HI-infused animals. The incidence of the peripheral nerve changes in the present study was lower compared to that of the previous 4-week study (up to 50% in HI-infused males in the present study versus 80% in the previous, and no change in HI-infused females in the present versus 70% in the previous) despite twice as long duration of hypoglycaemia. This is most likely explained by the lower blood glucose mean values obtained in the 4-week study, where whole-blood glucose ranged from 2 to 4 mM compared to 3.5-5 mM in the present study (plasma glucose ranges 3-5 mM versus 5-7 mM, respectively). Moreover, the low number of animals included in the 4-week study (6/sex per group) should be kept in mind. This study included twice the number of animals per group, thus providing more robust data.
In the present study, the nerve changes were more severe in HI-infused males compared to females. A similar tendency was seen in the above-mentioned 4-week study using the same infusion model (80% of males versus 70% of females displayed axonal degeneration) [8] . This finding is interesting, as there were no significant differences in blood glucose levels between males and females in the present study. However, the counter-regulatory increase in food consumption seen in the animals was more pronounced in the males. This suggests that males were more pressured with regard to glucose availability, consequently leading to a further increase in food consumption to compensate and maintain the tolerable decrease in blood glucose level seen in the study. Males received higher doses than females, which is most likely the cause of the increases counter-regulation compared to females; however, a direct damaging effect of insulin on the peripheral nerves should also be considered. As previously discussed in detail, insulin acts as a neuronal growth factor and serves as a promoter of axonal regeneration after injury of peripheral nerves [13] ; therefore, it is unlikely that hyperinsulinaemia would give rise to axonal degeneration. Most likely the hypoglycaemia caused the nerve changes, which in turn gave rise to the muscle changes [13] . This is also supported by a study in which normoinsulinaemic hypoglycaemic rats displayed peripheral neuropathy, while animals with hyperinsulinaemic normoglycaemia did not [14] . In contrast to muscle changes, nerve changes were only partly reversible based on severity, suggesting that a longer recovery period may lead to full recovery. In addition to nerve and skeletal muscle changes, 8 weeks of HI infusion resulted in an increased incidence of unilocular adipocytes in brown fat from HI-infused animals. This was most likely due to increased fat deposition in the brown fat caused by the increased food consumption and body-weights and/or the hyperinsulinaemia, as it is known that obesity in mice is associated with 'whitening' of brown adipocytes and that insulin stimulates fatty acid synthesis from extracellular glucose in brown adipose tissue [15] [16] [17] [18] . This 'whitening' is associated with an altered histological morphology of the brown adipocytes with enlarged lipid droplets and increased number of unilocular adipocytes resembling white adipocytes [16] [17] [18] , as seen in the present study. The islet cell atrophy in the pancreas was presumably due to b-cell hypotrophy and/or hypoplasia, as it is well-known that chronic hyperinsulinaemic hypoglycaemia in rats leads to reduced islet and b-cell size. This may be attributed to suppressed endogenous insulin production mediated through negative feedback by the hypoglycaemia and possibly also in part by the excess exogenous insulin levels [19] [20] [21] [22] [23] [24] [25] [26] [27] . The changes were reversed 4 weeks after cessation of infusion, which is in agreement with previous reports on reversibility of IHH-induced impairment of b-cell function [20, 28] . Expectedly, hypoglycaemia (approximately 50-70% of controls) triggered a counter-regulatory increase in food consumption in both males and females [8, [28] [29] [30] , accompanied by significantly increased body-weights in the HI-infused males. The decreases in body-weight relative liver and kidney weights were most likely related to this body-weight gain and possibly also depletion of glycogen caused by a hypoglycaemia-driven mobilization of glucose stores through gluconeogenesis. In line with this, counter-regulation to IIH was reflected by increased plasma urea and AST levels in HIinfused males, suggesting a hypoglycaemia-induced increase in hepatic gluconeogenesis to compensate for the low blood glucose levels [31] [32] [33] . Additionally, HI-High group males had a significant decrease in total urinary glucose output, which could suggest compensatory increased renal glucose reabsorption [34] . The increased plasma levels of sodium and chloride seen in HI-infused males is a known effect of insulin, caused by decreased urinary excretion of sodium and chloride mediated through increased reabsorption in the renal tubules [35] .
Absolute thymus weights were higher in HI-infused males, probably also attributable to increased body-weight and possibly thymic fat accumulation [36] , although no histopathological changes were noticed in the thymus. The increase in food consumption was most pronounced during the first weeks of infusion, whereas there was no difference in food consumption between HI-infused groups and the CTRL group towards the last week of dosing. The reason for this is unknown, but it is not unlikely that the animals become less responsive to the hypoglycaemia causing a decreased counter-regulation [37] . As plasma glucose levels were significantly lower on Day 57 compared to Day 8, the animals did not seem to become less insulin sensitive, however, the lower levels after 8 compared to one week of IIH may be explained by the lack of compensatory increase in food intake.
The abrupt cessation of HI infusion resulted in transiently increased plasma glucose levels in the HI-Low and HI-High groups up to 150% of controls, accompanied by a corresponding transient decrease in food consumption during the first days after infusion stop. In HI-High group males, which had 10% higher body-weights compared to CTRL group on Day 57, body-weights decreased down to CTRL group levels on Day R29. Additionally, this was accompanied by an increased total urinary glucose output by 118% in HI-High group males and 50-60% in HI-infused females, albeit these changes were not statistically significant as they were attributed to a few animals with high excretion. However, this could suggest that maximum capacity for renal glucose reabsorption is exceeded in these animals, which happens at blood glucose levels of approximately 11 mM [34] . The increased urinary glucose output was accompanied by a significantly increased total urinary volume, which could have caused the increase in total glucose output; however, as the specific gravity was decreased, the increase in urinary volume was most likely attributed to osmotic diuresis caused by the increased glucose levels [38] . The transient hyperglycaemia was most likely caused by suppressed endogenous insulin production [19, 20, 39] . Within a few days of ending HI infusion, blood glucose levels were restored and pancreatic islet volume (discussed above) returned to normal.
In addition to the histopathological changes in HI-infused animals mentioned above, some histopathological findings considered related to infusion in general were seen. Changes seen in lungs such as granulomas, thromboemboli with mineralization, and inflammatory cell infiltration were most likely attributed to the intravenous infusion as these are known changes seen in rats infused intravenously with saline [40, 41] . The reason for the apparent dose-response in the incidence of granulomas in lungs of HI-infused males is unknown, but could be incidental as this was not present in the HI-infused females and there was no difference in HI exposure between the HI-Low and HI-High group. Similarly, changes seen in relation to the implanted infusion catheter, such as in the skin, veins and lymph nodes, were comparable to those previously described after 4 weeks of infusion with this model as well as by others and were considered a chronic local foreign body response [8, 40] . This is further supported by the fact that there was no increase in levels of circulating leucocytes at sacrifice. Furthermore, 4 animals (3 controls and 1 HI-infused) had signs of severe infections contributing to death. All of these animals also showed cortical hypertrophy of the adrenals and/ or thymic involution/atrophy (data not shown), indicative of stress [42] , suggesting infections were opportunistic caused by the presence of the venous catheter. In addition to these animals, several animals had histopathological changes that indicated subclinical infections, such as inflammatory cell infiltration in liver and/or kidney. Such changes are not part of the usual findings seen in chronically infused rats [40] , but may be caused by pathogens gaining intravenous entry through the infusion system.
In conclusion, continuous HI infusion resulted in persistent hypoglycaemia in healthy euglycaemic rats. This IIH induced reversible histopathological changes in skeletal muscle and endocrine pancreatic tissue, and partly reversible histopathological changes in peripheral nerve and brown adipose tissue. Although the effects of hypoglycaemia per se cannot be differentiated from the effects of the hyperinsulinaemia in the present model, a literature review suggests that all of these findings were attributed either directly or indirectly to the exaggerated pharmacology of insulin, that is hypoglycaemia. Additionally, hypoglycaemia was accompanied by compensatory measures such as increased food consumption and most likely also increased gluconeogenesis, leading to increased bodyweights and plasma AST and urea levels. The present findings will support the future interpretation of results from non-clinical testing of new long-acting insulin analogues or other compounds rendering the rats persistently hypoglycaemic.
